ABSTRACT

The incidence of Benign Prostatic Hyperplasia (BPH) and erectile dysfunction (ED) are increasing with age and they adversely affect the quality of life. With the advancing age the prevalence of both BPH and ED are parallel to each other and with increases in the incidence of 29% to 68% have been reported in several studies. The etiology of these health problems is multifactorial; including hypertension, aging, diabetes mellitus and metabolic syndrome. In recent studies phosphodiesterase type 5 (PDE-5) inhibitors are used in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH and achieved successful results. In this review we examined the relationship between BPH/LUTS; also the using of PDE-5 in the LUTS treatment.